GlassScriptPhysician profile
Pranav Patel
NPI 1104059823
$2,310.48
in general payments reported to CMS, 2019-2025
27 companies · $431 in 2025
The $431 reported for 2025 was less than what a typical Uveitis and Ocular Inflammatory Disease provider received nationally (typical 2025 total: $471).
See the full distribution for Uveitis and Ocular Inflammatory Disease
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $151 · 2021: $463 · 2022: $277 · 2023: $426 · 2024: $395 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,214 · Entertainment: $20.44 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,213.82 |
| Entertainment | $20.44 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $294.09 | 2021-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $244.65 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $192.76 | 2022-2025 | Xipere, Vyzulta, Miebo |
| Alcon Vision LLC | $177.23 | 2020-2025 | Centurion, Rocklatan, Clareon |
| Abbvie INC. | $145.83 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $122.94 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $119.50 | 2022-2023 | Tyrvaya |
| Eyepoint US, INC. | $111.19 | 2021-2023 | |
| Horizon Therapeutics Plc | $99.84 | 2021 | |
| Rxsight INC | $96.38 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Allergan, INC. | $93.65 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $80.45 | 2021 | |
| Harrow Eye, LLC | $79.95 | 2024-2025 | Vevye |
| Glaukos Corporation | $58.98 | 2023 | |
| Dompe US, INC. | $58.39 | 2019-2025 | Oxervate |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $48.82 | 2021 | |
| Aerie Pharmaceuticals, INC. | $47.06 | 2020-2021 | |
| Rayner Intraocular Lenses Limited | $39.39 | 2022-2024 | Omidria, Rayone Emv, Rayone Aspheric |
| Sight Sciences, INC. | $37.63 | 2023-2024 | Omni Surgical System, Sion Surgical Instrument |
| Carl Zeiss Meditec, INC. | $34.48 | 2020 | |
| New World Medical,INC. | $31.57 | 2024 | Streamline, Clearpath, Ahmed Glaucoma Valve |
| Apellis Pharmaceuticals, INC. | $24.19 | 2025 | Syfovre |
| Optos, INC. | $20.44 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Acacia Pharma INC | $15.32 | 2021 | |
| Shire North American Group INC | $11.97 | 2019 | |
| Omeros Corporation | $11.90 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranav Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.